Megafine Pharma
Megafine Pharma is a 1995-founded Indian API manufacturer and CDMO operating two FDA-inspected cGMP facilities (270 KL capacity) producing niche, low-volume APIs in CNS, Urology, and Coagulation for global generic and innovator pharmaceutical customers across 60+ countries.
- Company typePrivate
- Founded1995
- HeadquartersMumbai, India
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Megafine Pharma does
Megafine Pharma, founded in 1995 and headquartered in Mumbai, is an Indian Active Pharmaceutical Ingredient (API) manufacturer and Contract Development & Manufacturing Organization (CDMO) operating two cGMP facilities in Nashik (Maharashtra) and Vapi (Gujarat) with a combined 270 KL of reactor capacity across 17 production blocks and 9 cleanrooms. Its commercial portfolio spans 27+ human and 5+ veterinary niche, low-volume, high-value APIs concentrated in CNS, Urology, and Coagulation therapeutics, supported by 88 patent submissions (11 granted) and an IP Management function covering patent landscaping and freedom-to-operate analysis. The company has been inspected by at least eight major regulatory authorities (US FDA, EMA/EDQM, TGA, Health Canada, MFDS, PMDA, ANVISA, COFEPRIS) and maintains 250+ global regulatory filings, 29 US DMFs, and 14 CEPs.
The business operates a B2B enterprise field-sales model, exporting approximately 98% of output to 60+ countries with direct engagement of global generic and innovator pharmaceutical customers. Revenue is generated through three streams: commercial API supply, advanced intermediates (including N-1 stage intermediates), and end-to-end CDMO services covering route scouting, process development, scale-up, analytical validation, and regulatory submissions. Pricing is quote-based, driven by volume, chemistry complexity, and regulatory requirements rather than disclosed list pricing. In October 2025, Motilal Oswal Alternates acquired a majority stake for Rs 460 crore alongside the founding Sanghvi Family, marking a transition from founder-led private ownership to PE-backed governance and providing capital for an ongoing 120 KL capacity expansion at Nashik.
Megafine Pharma firmographics
Firmographics- Name
- Megafine Pharma
- Legal name
- Megafine Pharma
- Website
- https://megafine.in
- Company type
- Private
- Founded year
- 1995
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Megafine Pharma is a 1995-founded Indian API manufacturer and CDMO operating two FDA-inspected cGMP facilities (270 KL capacity) producing niche, low-volume APIs in CNS, Urology, and Coagulation for global generic and innovator pharmaceutical customers across 60+ countries.
- Ownership category
- akta.pro rank
Megafine Pharma industry classification
Industry- Product category
- Active Pharmaceutical Ingredients (APIs)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule API & Intermediates CDMO (HLAGABAA)
- akta.pro secondary industries
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)
Keywords
Where Megafine Pharma is headquartered
LocationHeadquarters
- HQ city
- Mumbai
- HQ country
- India
- HQ region
- Asia
Offices3 records
Markets served
Megafine Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- API Manufacturing and Sales: Manufacturing and sale of Active Pharmaceutical Ingredients including niche, low-volume high-value molecules in therapeutic areas like CNS, Urology, and Coagulation. Revenue from commercial supply of APIs to global pharmaceutical companies.
- CDMO/Contract Manufacturing Services: End-to-end development and manufacturing support covering product lifecycle from early-stage route scouting and process development to scale-up, commercial manufacturing, and regulatory submissions including DMFs. Supports both generic and innovator companies.
- Advanced Intermediates: Development and manufacturing of high-quality advanced intermediates including N-1 stage intermediates, with DMF filings support. Enables customers to accelerate API development and filings cost-effectively.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Megafine Pharma product offering
Product offeringCore offering
Megafine Pharma is an innovation-driven manufacturer and global supplier of Active Pharmaceutical Ingredients (APIs) and advanced intermediates, operating two US FDA-inspected cGMP facilities in Nashik and Vapi, India with combined 270 KL reactor capacity. The company also delivers CDMO services spanning early-stage route scouting, process development, scale-up, commercial manufacturing, and regulatory submissions including DMFs and CEPs, serving global generic and innovator pharmaceutical companies across 60+ countries.
Product overview
Megafine Pharma is an innovation-driven manufacturer offering a unified portfolio of APIs, Advanced Intermediates, and CDMO services. The core products include 27+ human use APIs (targeting CNS, Urology, Coagulation therapeutic areas) and 5+ veterinary APIs, complemented by Advanced Intermediates including N-1 stage intermediates. The CDMO service offering provides end-to-end support from R&D through commercial manufacturing. Supporting services include AR&D for analytical development, IPM for patent management, and Quality Control and Assurance. The company operates two cGMP manufacturing facilities in Nashik and Vapi, India, with combined capacity of 270 KL across 17 production blocks and 9 cleanrooms.
Differentiator
Problem solved
Functional benefit
Products and services
- Active Pharmaceutical Ingredients (APIs) Megafine's core commercial offering consists of niche, R&D-driven Active Pharmaceutical Ingredients targeting CNS, Urology, and Coagulation therapeutic areas. The portfolio includes 27+ human-use APIs and 5+ veterinary APIs manufactured under cGMP with strong IP support and global regulatory expertise, supplied to global generic and innovator pharmaceutical companies.
- Advanced Intermediates Megafine develops and manufactures high-quality advanced intermediates, including N-1 stage intermediates, with DMF filings support and regulatory documentation to enable customers to accelerate API development and regulatory submissions cost-effectively.
- CDMO (Contract Development and Manufacturing Organization) Services Contract Development and Manufacturing Organization services providing end-to-end support from early-stage route scouting and process development through scale-up, commercial manufacturing, and regulatory submissions (DMFs), delivered by dedicated project teams to global generic and innovator pharmaceutical companies seeking a partner from concept to commercial supply.
Companies that use Megafine Pharma
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Megafine Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Megafine Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Pharmaceutical Supply Chain Initiative (PSCI)minorMegafine is a member of the Pharmaceutical Supply Chain Initiative (PSCI), demonstrating commitment to ethical and sustainable supply chain practices in the pharmaceutical industry.
Scale indicators8 records
Recent moves9 records
Expansion highlights4 records
Megafine Pharma competitors and assessment
Company assessmentDirect peers
- Divis Laboratories: India's leading API and intermediates manufacturer with extensive US FDA-inspected facilities and a similar export-focused, niche-molecule strategy. Both companies compete in custom synthesis, generics API supply, and innovator CDMO services with comparable regulatory footprints.
- Laurus Labs: Indian API manufacturer with strong exposure to small-molecule APIs, ARV, oncology, and CDMO services. Comparable in being an R&D-driven, export-focused, FDA-inspected API specialist serving regulated markets globally.
- Aarti Industries: Indian specialty chemicals and pharmaceutical intermediates manufacturer with significant API exposure. Competes in advanced intermediates, custom synthesis, and regulated-market supply, with similar export orientation.
- Piramal Pharma Solutions: Global CDMO offering API development and manufacturing, including small-molecule and peptide services. Direct peer in the CDMO space, competing for innovator pharma contract research, development, and commercial supply engagements.
- Jubilant Pharmova (Jubilant Life Sciences): Indian API and CDMO player with US FDA-inspected facilities, offering small-molecule APIs, radiopharma, and contract manufacturing services. Comparable regulatory depth, customer base in regulated markets, and integrated API-CDMO model.
- Hikal: Indian manufacturer of APIs, intermediates, and contract research and manufacturing services. Similar in targeting niche, complex chemistries with FDA/EMA compliance and serving global innovator and generic pharma customers.
Broad incumbents
- Aurobindo Pharma: Large Indian pharmaceutical company with vertically integrated API operations serving as a significant supplier of small-molecule APIs to global generics. While much larger and more diversified than Megafine, it competes in similar small-molecule API categories and global tender markets.
- Dr. Reddy's Laboratories: Major Indian pharma with in-house API manufacturing for its generic formulations and external API supply. Competes with Megafine in regulated-market small-molecule API supply and has a substantial CDMO/API services business.
Emerging players
- Shilpa Medicare (API Division): Indian API and intermediates manufacturer with growing CDMO capabilities, focused on niche oncology and complex small molecules. Comparable as an emerging specialist in high-value, complex APIs targeting regulated markets.
- Sai Life Sciences: Indian CDMO offering API process development and manufacturing services for global innovator pharma. Comparable in targeting the niche CDMO opportunity with FDA-inspected facilities, though it does not manufacture its own proprietary API portfolio to the same extent as Megafine.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Megafine Pharma social profiles
Digital presenceMegafine Pharma compliance and trust
Trust signalCompliance6 records
Megafine Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Megafine Pharma leadership team
Management profileNumber of profiles
Megafine Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Megafine Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Megafine Pharma
What does Megafine Pharma do?
Megafine Pharma is an innovation-driven manufacturer and global supplier of Active Pharmaceutical Ingredients (APIs) and advanced intermediates, operating two US FDA-inspected cGMP facilities in Nashik and Vapi, India with combined 270 KL reactor capacity. The company also delivers CDMO services spanning early-stage route scouting, process development, scale-up, commercial manufacturing, and regulatory submissions including DMFs and CEPs, serving global generic and innovator pharmaceutical companies across 60+ countries.
Is Megafine Pharma a public or private company?
Megafine Pharma is a private company. It is classified as private equity controlled and is currently operating.
When was Megafine Pharma founded?
Megafine Pharma was founded in 1995. It employs 101 to 250 people.
Where is Megafine Pharma based?
Megafine Pharma is headquartered in Mumbai, India, in the Asia region.
How does Megafine Pharma make money?
Three revenue lines are on record. API Manufacturing and Sales are the primary driver. The others are CDMO/Contract Manufacturing Services and advanced Intermediates.
Who are Megafine Pharma's main competitors?
Direct peers on record are Divis Laboratories, Laurus Labs, Aarti Industries, Piramal Pharma Solutions, Jubilant Pharmova (Jubilant Life Sciences) and Hikal. Broad incumbents are Aurobindo Pharma and Dr. Reddy's Laboratories. Emerging players are Shilpa Medicare (API Division) and Sai Life Sciences.
Does Megafine Pharma have an API?
No public API is recorded for Megafine Pharma.
What industry is Megafine Pharma in?
Megafine Pharma's product category is Active Pharmaceutical Ingredients (APIs). Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325412 and its SIC code is 2834.